First-in-man study of the PSMA Minibody IR800-IAB2M for molecularly targeted intraoperative fluorescence guidance during radical prostatectomy
European Journal of Nuclear Medicine and Molecular Imaging · 2024-08 · 51 (10) · 3009-3025
DOI: 10.1007/s00259-024-06713-x ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Nuclear Medicine and Molecular Imaging, online erschienen am 10.06.2024. Verfasst von Freddie C Hamdy und 27 weiteren Autor:innen. Beteiligte Einrichtung: Nuffield Department of Surgical Sciences, University of Oxford, Old Road Campus Research Building, Headington, Oxford, OX3 7DQ, UK. Freddie.Hamdy@nds…. Hauptthemen laut MEDLINE: Prostatectomy, Prostatic Neoplasms, Glutamate Carboxypeptidase II, Antigens, Surface. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Purpose
Prostate-specific membrane antigen (PSMA) is increasingly used to image prostate cancer in clinical practice. We sought to develop and test a humanised PSMA minibody IAB2M conjugated to the fluorophore IRDye 800CW-NHS ester in men undergoing robot-assisted laparoscopic radical prostatectomy (RARP) to image prostate cancer cells during surgery.
Methods
The minibody was evaluated pre-clinically using PSMA positive/negative xenograft models, following which 23 men undergoing RARP between 2018 and 2020 received between 2.5 mg and 20 mg of IR800-IAB2M intravenously, at intervals between 24 h and 17 days prior to surgery. At every step of the procedure, the prostate, pelvic lymph node chains and extra-prostatic surrounding tissue were imaged with a dual Near-infrared (NIR) and white light optical platform for fluorescence in vivo and ex vivo. Histopathological evaluation of intraoperative and postoperative microscopic fluorescence imaging was undertaken for verification.
Results
Twenty-three patients were evaluated to optimise both the dose of the reagent and the interval between injection and surgery and secure the best possible specificity of fluorescence images. Six cases are presented in detail as exemplars. Overall sensitivity and specificity in detecting non-lymph-node extra-prostatic cancer tissue were 100% and 65%, and 64% and 64% respectively for lymph node positivity. There were no side-effects associated with administration of the reagent.
Conclusion
Intraoperative imaging of prostate cancer tissue is feasible and safe using IR800-IAB2M. Further evaluation is underway to assess the benefit of using the technique in improving completion of surgical excision during RARP. Registration ISCRCTN10046036: https://www.isrctn.com/ISRCTN10046036 .
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Nuffield Department of Surgical Sciences, University of Oxford, Old Road Campus Research Building, Headington, Oxford, OX3 7DQ, UK. Freddie.Hamdy@nds.ox.ac.uk.
- Oxford University Hospitals NHS Trust, Oxford, UK. Freddie.Hamdy@nds.ox.ac.uk.
- Nuffield Department of Surgical Sciences, University of Oxford, Old Road Campus Research Building, Headington, Oxford, OX3 7DQ, UK.
- Oxford University Hospitals NHS Trust, Oxford, UK.
- Department of Oncology, University of Oxford, Oxford, UK.
- Oxford Clinical Trials Research Unit and Centre for Statistics in Medicine, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK.
ORCID-Profile: Freddie C Hamdy, Alastair D Lamb, Iain D C Tullis, Clare Verrill, Ines Rombach, Srinivasa R Rao, Richard Colling, Paul R Barber, Davide Volpi, J Francisco Lopez, Altan Omer, Aimi Hewitt, Claire Thomson, Tom Leslie, Richard J Bryant, Anna M Wu, Borivoj Vojnovic
Zitieren
APA
Hamdy, F. C., Lamb, A. D., Tullis, I. D. C., Verrill, C., Rombach, I., Rao, S. R., Colling, R., Barber, P. R., Volpi, D., Barbera-Martin, L., Lopez, J. F., Omer, A., Hewitt, A., Lovell, S., Niederer, J., Lambert, A., Snoeck, J., Thomson, C., Leslie, T., …, & Vojnovic, B. (2024). First-in-man study of the PSMA Minibody IR800-IAB2M for molecularly targeted intraoperative fluorescence guidance during radical prostatectomy. European Journal of Nuclear Medicine and Molecular Imaging, 51(10), 3009-3025. https://doi.org/10.1007/s00259-024-06713-x
Vancouver
Hamdy FC, Lamb AD, Tullis IDC, Verrill C, Rombach I, Rao SR, et al. First-in-man study of the PSMA Minibody IR800-IAB2M for molecularly targeted intraoperative fluorescence guidance during radical prostatectomy. European Journal of Nuclear Medicine and Molecular Imaging. 2024;51(10):3009-3025. doi:10.1007/s00259-024-06713-x
BibTeX
@article{Hamdy2024,
author = {Hamdy, Freddie C and Lamb, Alastair D and Tullis, Iain D C and Verrill, Clare and Rombach, Ines and Rao, Srinivasa R and Colling, Richard and Barber, Paul R and Volpi, Davide and Barbera-Martin, Luis and Lopez, J Francisco and Omer, Altan and Hewitt, Aimi and Lovell, Shelagh and Niederer, Jane and Lambert, Adam and Snoeck, Joke and Thomson, Claire and Leslie, Tom and Bryant, Richard J and Mascioni, Alessandro and Jia, Fang and Torgov, Michael and Wilson, Ian and Gudas, Jean and Wu, Anna M and Olafsen, Tove and Vojnovic, Borivoj},
title = {First-in-man study of the PSMA Minibody IR800-IAB2M for molecularly targeted intraoperative fluorescence guidance during radical prostatectomy},
journal = {European Journal of Nuclear Medicine and Molecular Imaging},
year = {2024},
volume = {51},
number = {10},
pages = {3009--3025},
doi = {10.1007/s00259-024-06713-x}
}
EUVIMED